tbuckley/cabot-search huggingface dataset:
Individualized adjuvant chemotherapy (ACT) based on quantitative excision repair cross-complementing 1 (ERCC1) mRNA expression: A randomized phase II trial in Japanese patients with completely resected non-small cell lung cancer (NSCLC).
Authors: S. Nagase, M. Tsuboi, K. Suzuki, T. Ohira, N. Ikeda
Journal: Journal of Clinical Oncology (2010)

e17506 Background: Cisplatin-based ACT improves survival in patients with completely resected NSCLC. By immunohistochemistry (IHC), cisplatin-based ACT, as compared with observation, significantly prolonged survival among patients with ERCC1-negative tumors but not among patients with ERCC1-positive tumors. Median overall survival was significantly longer in patients with low ERCC1 mRNA expression (mERCC1) tumors compared to patients with high mERCC1 tumors for advanced NSCLC received cisplatin-based CT (CCR 2002). A prospective randomized trial has demonstrated that selection of double-agent CT based on mERCC1 for advanced NSCLC is feasible and would improve overall response rate (JCO 2007). Methods: Two-step registration was applied, because of technical aspects for measuring mERCC1 level. Patients with clinical stage IB, II, or IIIA NSCLC were randomly assigned in a 1:2 ratio to either control (C) or individualization (I) arm. Patients were eligible if they had pathological stage IB, II, or IIIA NSCLC, complete resection. RNA was isolated from the tumor tissue obtained by the operation, and mERCC1 analysis was performed by quantitative RT-PCR assays. We used a cutoff value of mERCC1 with 6.7. Patients in C arm received gemcitabine/carboplatin (GCb), and in I arm based on mERCC1 levels: those with low ERCC1 levels (L- ERCC1) received GCb; those with high ERCC1 levels (H-ERCC1) received gemcitabine/uracil-tegafur. This study was designed to evaluate exploratorily the efficacy of individualized ACT based on mERCC1 as the primary endpoint in 2-year relapse free survival. Results: From February 2008 to September 2009, 81 patients were registered to this trial. Fifty (93%) of I arm in 54 were L-ERCC1, and four (7%) were H-ERCC1. We stopped this trial once because most were L-ERCC1. We discussed to confirm the correlation of mERCC1 and ERCC1 protein expression (pERCC1) by IHC using tumor tissue samples of I arm. Conclusions: In patients, receiving GCb, of most L-ERCC1 of I arm, we are going to investigate which relates to survival in mERCC1 and pERCC1 strongly in the future. No significant financial relationships to disclose.
Retrospective claims analysis of palliative care costs and survival in a U.S. metastatic renal cell (mRCC) population.
Authors: Henry J. Henk, Connie Chen, Agnes Benedict, Jane Sullivan, April Teitelbaum
Journal: Journal of Clinical Oncology (2012)

433 Background: Survival and costs outcomes for patients with mRCC receiving palliative or best supportive care (BSC) after stopping active therapy have been poorly characterized. This information is important to understand how resources are utilized at the end of life and to put current treatment costs into perspective. The objective of this retrospective database analysis was to examine survival and costs associated with BSC after receiving 1 or 2 lines of mRCC treatment. Methods: A retrospective cohort analysis using claims data from commercially insured or Medicare Advantage (MCR) enrollees of a large US health plan, with medical and pharmacy benefits. The study cohort consisted of patients with an index diagnosis for RCC [ICD-9-CM 189.0] from 1/1/07 to 6/30/10 initiating any of the following treatments from 30 days prior to index date through disenrollment: sunitinib, temsirolimus, sorafenib, bevacizumab, everolimus, pazopanib, cytokines. Patients were required to have a 6 mos. continuous enrollment ± index date (patients disenrolling due to death within the 6 mos. were retained). Lines of therapy (LOT) were identified based on prescription fill and administration dates, began following the last LOT and continued until disenrollment. Health care costs reported represent the health plan + patient paid amount. Results: The overall study cohort (n=274) was 73% male; mean (±SD) age 63.3 ± 11.1 yr. with the majority of patients commercially insured (80% vs 20% MCR). The majority started BSC following 1 st LOT (68% vs 32%). Median survival from start of BSC was similar following 1 st and 2 nd LOT (126 and 118 days). The mean (median) duration of BSC after 1 LOT was 223 (114) days and 176 (109) days for 2 LOT. Total health care costs incurred during BSC averaged $50,187 ± 96,984 and $37,294 ± 51,101 and monthly costs were similar ($10,284 ± 17979) after 1 and 2 LOT, respectively. In both cases, inpatient hospital costs represented the largest proportion of these costs (47%) while outpatient costs represented 36%. Conclusions: Our study estimating BSC survival and costs in patients with mRCC based on US claims data found monthly cost of $10, 284. These estimates suggest that BSC costs are not insignificant.
Differences in perceptions of smoking and second-hand smoke (SHS) in palliative and nonpalliative patients with cancer.
Authors: Rahul Mohan, Devon Alton, Jie Su, Yuyao Song, Delaram Farzanfar, Olivia Krys, Tom Yoannidis, Robin Milne, M Catherine Brown, Andrew J. Hope, Doris Howell, Jennifer M. Jones, Peter Selby, Wei Xu, David Paul Goldstein, Meredith Elana Giuliani, Geoffrey Liu, Lawson Eng
Journal: Journal of Clinical Oncology (2016)

251 Background: With improvements in cancer therapies, palliative patients with cancer now enjoy improved and sometimes prolonged survival. Continued smoking after a cancer diagnosis negatively impacts treatment response/toxicities, survival and quality of life and is influenced by SHS exposure. Little is known about the perceptions of palliative patients with cancer in comparison to patients who are considered potentially curative, on smoking after a cancer diagnosis and of SHS exposure. We assessed such potential differences in perception. Methods: Patients with cancer across all sites were surveyed with respect to their smoking habits and perceptions on how smoking and SHS influences cancer-related QofL, fatigue and overall survival (OS). Review of patient charts confirmed which patients were considered palliative versus potentially curative. Multivariable logistic regression models assessed for associations between treatment intent and patient perceptions, adjusted for significant co-variables. Results: Among 985 patients with cancer, 22% were considered palliative; 23% of surveyed patients smoked at diagnosis; 10% continued smoking at follow-up. Most patients perceived that continued smoking and SHS exposure negatively impacted QofL (continued smoking: 83%, SHS: 82%), fatigue (83%, 79%) and OS (86%, 81%). Palliative patients were more likely to believe that SHS worsened their cancer-related fatigue (adjusted odds ratio (aOR) = 1.65, 95% CI [1.05-2.56], P = 0.03) and worsened OS (unadjusted OR = 1.92, [1.12-3.33], P= 0.02; aOR = 1.56 [0.98-2.50], P = 0.06). Yet palliative/non-palliative status was not found to be associated with perceived benefits of smoking cessation on QofL, fatigue, or OS (P &gt; 0.10, all comparisons). Conclusions: When compared with non-palliative patients, palliative patients with cancer perceived a greater negative impact of SHS on fatigue and survival, but had similar views of continued smoking after a cancer diagnosis. We are encouraged that palliative status did not lead to patients having diluted perceptions on the negative impact of smoking on cancer outcomes. Health care providers should continue to focus on the positive impacts of smoking cessation and SHS in this setting.
5–azacitidine Treatment of Imminent Relapse Defined by Decreasing Donor CD34+ Progenitor Subset Chimerism in Patients with CD34+ High-Risk Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML) after Allogeneic Stem Cell Transplantation.
Authors: Uwe Platzbecker, Joergen Radke, Alexander Kiani, Malte Bonin, Eray Goekkurt, Uta Oelschlägel, Brigitte Mohr, Gerhard Ehninger, Martin Bornhauser, Christian Thiede
Journal: Blood (2008)
TRU-016, An Anti-CD37 SMIP™ Biologic, In Combination with Other Therapeutic Drugs In Models of Non-Hodgkin's Lymphoma
Authors: Paul A. Algate, Jennifer Wiens, Christy Nilsson, Mien Sho, Debra T. Chao, Gary C. Starling, John C. Byrd, Brian Gordon
Journal: Blood (2010)
Prevalence of low bone mass and osteoporosis in patients with cancer: Program for healthy aging<i>. </i>
Authors: Beatrice Jara-Almonte Edwards, Ming Sun, Holly Michelle Holmes, Heather Valladarez, Vu Nguyen, Peter Khalil, Juhee Song
Journal: Journal of Clinical Oncology (2016)

30 Background: Older adults, 65 years of age and older, with cancer may be at higher risk for low bone mass or osteoporosis, however, the exact magnitude of this condition is unknown. It is postulated that the etiology of low bone mass and osteoporosis in cancer may be a combination of age-related and cancer therapy related bone loss. Methods: We conducted a retrospective cohort analysis, of older adult cancer patients evaluated at the Program for Healthy Aging at MD Anderson from January 1, 2013 through March 31, 2015. Bone mineral density (BMD) was assessed with a Hologic W densitometer, with a CV% of 1%. Information on prior fractures and falls were also collected. Results: One hundred and nine patients with Bone density tests were included in the analysis, with males (n = 57) constituting 52% of cases, the mean age was 77 years, range 65 – 93 years. Race: white (n = 79, 74.5%), African- American (n = 23, 21.2%), Asian (n = 4, 3.8%). Ethnicity: Latino (n = 8, 11.4%). Cases included hematologic cancers (n = 41, 37.6%), breast cancer (n = 19, 17.4%), prostate cancer (n = 15, 13.8%), gastrointestinal cancers (n = 10, 9.2%), and bladder and lung cancer each (n = 6, 5.5%). Low bone mass and osteoporosis was identified in 87 cases (80%). Only 26 cases reported falls in the preceding 6 months, while 11 cases had a prior fracture after the age of 50 years. Additional risk factors for falls and fractures included cognitive impairment, malnutrition, and polypharmacy. Conclusions: Low bone mass and osteoporosis are highly prevalent conditions in older patients with hematologic and solid malignancies. A greater awareness of such, should allow for effective interventions in order to prevent fractures and their negative impact on quality of life.
Use of class III beta tubulin to predict efficacy from paclitaxel- or docetaxel-based chemotherapy in patients with advanced gastric cancer.
Authors: J. Ahn, M. Jung, H. Chang, X. Zhang, H. Jeung, T. Kim, J. K. Roh, H. C. Chung, S. Y. Rha
Journal: Journal of Clinical Oncology (2011)

52 Background: To predict clinical outcome in patients with advanced gastric cancer (AGC) received paclitaxel or docetaxel based chemotherapy, we evaluated expression of class III beta tubulin (bTubIII). Methods: Expression of bTubIII was evaluated by immunohistochemistry (IHC) on formalin-fixed, paraffin-embedded tumors from the primary gastric cancer. Tumors were classified as bTubIII “low” and “high” according to median of IHC score [intensity (0-3) × portion (0-100)]. The expression of bTubIII was investigated for their association with clinical outcomes of efficacy and toxicity. Results: One hundred twenty-four AGC pts who were treated with paclitaxel or docetaxel combined with an infusional 5-fluorouracil and low-dose leucovorin as first and second-line palliative chemotherapy were enrolled. Thirty-three patients (26.7%) were confirmed to have high expression of bTubIII. The patients with high expression of bTubIII showed higher disease control rate (DCR) and longer progression-free survival (PFS) than those with low expression in patients treated with paclitaxel (79.3 % vs. 57.3 %, p = 0.039, and 3.0 months vs. 1.5 months, p = 0.073). By contrast, there was no difference of DCR and PFS according to expression of bTubIII in patients treated with docetaxel. The expression of bTubIII was not associated with toxicity in both patients treated with paclitaxel or docetaxel. Conclusions: The expression of bTubIII may be a predictive marker in AGC patients received paclitaxel based chemotherapy, but not docetaxel. No significant financial relationships to disclose.
Comparison of Outcomes Between Unrelated Donor and Sibling Donor Transplant in Adult Patients with Severe Aplastic Anemia: A Single Center Retrospective Study
Authors: Sung-Eun Lee, Jae-Ho Yoon, Seung-Hwan Shin, Seung-Ah Yahng, Byung-Sik Cho, Ki-Sung Eom, Yoo-Jin Kim, Seok Lee, Chang-Ki Min, Hee-je Kim, Seok-Goo Cho, Dong-Wook Kim, Woo-Sung Min, Chong-Won Park, Jong Wook Lee
Journal: Blood (2012)
Identification of malignancy-associated change in buccal mucosa with partial wave spectroscopy (PWS): A potential biomarker for lung cancer risk
Authors: T. A. Hensing, H. Subramanian, H. K. Roy, D. Breault, Z. Bogojevic, D. Ray, N. Hasabou, V. Backman
Journal: Journal of Clinical Oncology (2008)

11045 Background: The inability to develop a robust screening test to identify early disease is a major reason that lung cancer (LC) remains the leading cause of cancer deaths among Americans. Field carcinogenesis is well established in LC and has been exploited by genomic studies in histologically normal bronchial mucosa to predict concurrent neoplasia. Emerging evidence suggests that the field may extend to the buccal epithelium however no accurate means of identifying these changes are currently available. Our group has pioneered the development of light scattering technologies for detection of neoplasia (Nature 2000) and more recently field carcinogenesis (Gastro 2004, Clin Cancer Res, 2006, 2007). A novel technique termed partial wave spectroscopy (PWS) allows heretofore unparalleled information regarding the nanoscale cellular architecture thus serving as a marker for the genetic/epigenetic changes of field carcinogenesis. In particular, PWS measures disorder strength (Ld) of cell nanoarchitecture. We investigated whether nanoarchitectural abnormalities of the buccal epithelium could predict concurrent lung cancer. Methods: Cases were pts with confirmed or suspected LC. Controls had COPD (to avoid confounding by smoking history). Ld was analyzed from buccal mucosal brushings. Results: Buccal mucosal brushings were obtained from 65 pts (28 COPD/37 LC (33 non-small cell and 4 small cell). Cases and controls were well matched with regards to gender, age (median age 71 COPD/70 LC) and median pack-years (78 ±38 COPD/59±46 LC). There was significantly increased disorder in the nanoarchitecture of the buccal cells in LC pts compared to control (p<0.001). From this preliminary dataset, we calculated the sensitivity (79%) and specificity (94%) and area under ROC curve (0.91) Conclusions: We demonstrate, for the first time, that optical interrogation of the buccal mucosa was able to discriminate pts with LC from those high-risk patients who were neoplasia free. If confirmed in ongoing larger scale studies, this technique may have promise as a pre-screen for techniques such as low-dose CT. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration American BioOptics
Lack of predictive value of reticulocalbin-1 and GST-Pai alterations for efficacy of postoperative adjuvant chemotherapy consisting of cisplatin plus vindesine in patients with p-stage IIIA-N2 non-small cell lung cancer (NSCLC) (JCOG9304A)
Authors: M. Tsuboi, T. Hirano, T. Ohira, H. Kato, T. Mitsudomi, R. Tsuchiya, H. Tada, Y. Ichinose
Journal: Journal of Clinical Oncology (2005)

7316 Background: We have been sought for molecular markers for prediction of prognosis or chemo-sensitiby to achieve “individualized therapy”. We detected a polypeptide (molecular weight 44.0 kDa) which significantly decreased in expression level in CDDP-resistant cells by comparing the two-dimensional polyacrylamide gel electrophoresis (2-DE) patterns of the parent strain and CDDP-resistant cultured lung cancer cells (H69 and PC14). The amino acid sequence suggested that this polypeptide might be homologous with reticulocalbin-1 (RCN-1). In our in-house cases with adjuvant chemotherapy using platinum-based drugs with positive expression of RCN-1 was a better outcome obtained compared with cases without RCN-1 expression. Methods: To evaluate which molecular markers would be define subset of patients who would be benefited from postoperative adjuvant chemotherapy. Results: Abnormal expression of RCN-1 and GST-Pai. was detected in 76% and 42%, respectively. There was no relationship between each molecular alteration and clinical-pathologic characteristics such as gender, age, or treatment arm. In addition, in none of patient subsets with or without above molecular markers, survival was significantly affected by postoperative adjuvant chemotherapy (RCN-1+P=0.2980, RCN-1-P=0.5873; GST-pai+P=0.7291, GST-pai-P=0.3398). Conclusions: Although the number of patients was small and our previous study suggested the reticulocalbin-1 molecule might have some kind of involvement in the chemical tolerance mechanism of platinum-based drugs, it is concluded that in this retrospective analysis these markers failed to predict survival or response to the adjuvant chemotherapy consisting of cisplatin and vindesine in NSCLC patients with N2 disease. No significant financial relationships to disclose.
Selection of Donors with Favorable KIR B Genotypes for Unrelated Hematopoietic Cell Transplantation Results in Superior Relapse Protection and Better Relapse-Free Survival for Patients with AML.
Authors: Sarah Cooley, Lisbeth Guethlein, Elizabeth Trachtenberg, Martha Ladner, Xianghua Luo, Chap T Le, Tao Wang, John P. Klein, Steven G.E. Marsh, Stephen Spellman, Michael D Haagenson, Daniel J. Weisdorf, Peter Parham, Jeffrey S. Miller
Journal: Blood (2009)
The Oral, Direct Factor Xa Inhibitor BAY 59-7939 Does Not Cross-React with Anti-Heparin/PF4 (Heparin-Induced Thrombocytopenia) Antibodies.
Authors: Jeanine M. Walenga, Debra Hoppensteadt, Omer Iqbal, Brian Neville, Walter P. Jeske, Margaret Prechel, Harry L. Messmore, Frank Misselwitz, Mamdouh Bakhos
Journal: Blood (2005)
Comprehensive profiling of renal medullary and collecting duct carcinomas.
Authors: Thai Huu Ho, Jeffrey Swensen, Anatole Ghazalpour, Ondrej Hes, Melissa L. Stanton, Monika Joshi, Souzan Sanati, Priyanka Purnanada, David Arguello, Sandeep K. Reddy, Zoran Gatalica
Journal: Journal of Clinical Oncology (2016)

572 Background: Renal medullary carcinoma (RMC) is an aggressive malignancy affecting predominantly young African Americans with sickle cell trait (SCT) or disease (SCD), while a pathologically similar collecting duct carcinoma (CDC) affects patients without sickle cell trait. Clinical responses to chemotherapy and IL-2 in RMC/CDC are poor and novel therapies are needed. Methods: 9 patients with RMC (ages 13-58 y. o., all male) and 15 patients (ages 26-74 y. o., M:F = 13:2) with collecting duct carcinoma (CDC) were studied. Expression of PD-L1 was evaluated with 2 monoclonal antibodies (SP142 and SP263) and tumor infiltrating lymphocytes (TIL) were evaluated for PD1 expression (MRQ-22 antibody) using immunohistochemistry (IHC). Additional studies included ALK protein expression (D5F3 antibody), gene translocation (break apart FISH), next generation sequencing (NGS), and microsatellite instability (MSI). Results: Cancer cell PD-L1 expression above the threshold ( ≥ 2+, ≥ 5%) was seen in 7/9 RMC and 5/13 CDC cases. Concordance between 2 PD-L1 antibodies was 94.4%. PD-1+ TIL were absent in 6/18 cases and variably present in 12/18 cases (from 1 to &gt; 15 TIL/40x power field). No MSI was detected in any of the cases tested (0/6). No case expressed ALK protein, but one case of CDC showed ALK gene re-arrangement. Mutations were identified in SMARCB1, FH, TP53 (3x), ATM, BRCA2, CHEK2 (2x), NF2 (3x), SETD2, and CDKN2A. No mutations in VHL or KDR were detected. One patient with RMC (and SCT) achieved complete clinical remission after treatment with bevacizumab plus paclitaxel. Conclusions: RMC and CDC strongly express PD-L1 in the majority of cases (12/22), suggesting that these patients may benefit from targeting the PD-L1/PD1 interaction. The absence of MSI in these cancers indicates a different mechanism of PD-L1 upregulation from colorectal carcinomas. Consistent with our previous study that showed frequent activation of (pseudo)hypoxia-induced pathways in RMCs (Human Pathology 2011;42:1979), we describe a case of RMC successfully treated with anti-VEGF therapy.
Baseline subject characteristics to predict compliance with study-mandated prostate biopsy in men at risk of prostate cancer: Results from REDUCE.
Authors: Sean Fischer, Xizi Sun, Lauren E. Howard, Daniel Moreira, Ramiro Castro, Gerald L. Andriole, Adriana Vidal, Stephen J. Freedland
Journal: Journal of Clinical Oncology (2016)

6 Background: Study compliance is crucial when the study outcome is determined by an invasive procedure, such as prostate biopsy. To investigate predictors of compliance in study-mandated prostate biopsies, we analyzed demographic, clinical and reported lifestyle data from the REDUCE trial. Methods: We retrospectively identified 8,062 men from REDUCE with at least 2-years of follow-up, and used multivariable logistic regression to test the association between baseline demographic and clinical characteristics and undergoing the study-mandated prostate biopsy at 2 years. We then examined whether missing any of these data was associated with undergoing a biopsy. Results: In REDUCE, 20% of men did not undergo a 2-year biopsy.On multivariable analysis, non-North American region was predictive of 35-55% increased likelihood of undergoing a 2-year biopsy (p ≤ 0.001). Being enrolled at a center that enrolled &gt;10 subjects (2nd and 3rd tertile) was associated with a 40-49% increased likelihood of undergoing a 2-year biopsy (p &lt; 0.001). Missing one or more baseline variables was associated with a 25% decreased likelihood of undergoing a 2-year biopsy (OR = 0.75; p = 0.002). Conclusions: In REDUCE, men outside North America, those at higher volume centers, and those with complete baseline data were more likely to undergo study mandated 2-year biopsies. Given prostate biopsy is becoming increasingly utilized as an endpoint in trials that are often multi-national, regional differences in compliance should be considered when designing future trials. Likewise, efforts are needed to ensure compliance in low-volume centers or among subjects missing baseline data.